Biodexa Pharmaceuticals (BDRX) EBT Margin (2015 - 2020)

Biodexa Pharmaceuticals has disclosed EBT Margin across 6 years of filings, most recently posting 13970.24% for Q4 2020.

• In Q4 2020, EBT Margin fell 1155365.0% year-over-year to 13970.24%; the TTM figure through Dec 2020 stood at 1389.08% (down 114171.0% YoY), while the FY2023 annual figure was 1964.57%, down 75026.0% from the prior year.
• EBT Margin came in at 13970.24% for Q4 2020 at Biodexa Pharmaceuticals, down from 10630.36% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 99.8% in Q4 2017 to a low of 13970.24% in Q4 2020.
• Average EBT Margin over 5 years is 4606.16%, with a median of 1368.01% recorded in 2018.
• Year-over-year, EBT Margin jumped 22297 bps in 2016 and tumbled 1155365 bps in 2020.
• Over 5 years, EBT Margin stood at 200.57% in 2016, then soared by 50 bps to 99.8% in 2017, then tumbled by 220 bps to 319.42% in 2018, then sank by 657 bps to 2416.59% in 2019, then slumped by 478 bps to 13970.24% in 2020.
• Per Business Quant data, the three most recent EBT Margin figures were 13970.24% in Q4 2020, 10630.36% in Q3 2020, and 2416.59% in Q4 2019.